In vivo depletion of T lymphocyte-specific transcription factors by RNA interference

Cell Cycle

Volumn 9, Issue 14, 2010, Pages 2902-2907

  Tesniere, Antoine ^a,b,c,d   Abermil, Nassera ^a,b,c   Schlemmer, Frederic ^a,b,c   Casares, Noelia ^a,b,c   Kepp, Oliver ^a,b,c   Pequignot, Marie ^a,b,c   Michaud, Mickael ^a,b,c   Martins, Isabelle ^a,b,c   Senovilla, Laura ^a,b,c   Zitvogel, Laurence ^b,c,e   Kroemer, Guido ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d université Paris Cité   (France)

^e University Paris XI   (France)

Author keywords

Anthracyclines; Apoptosis; GATA3; Immunogenic cell death; siRNA; T bet

Indexed keywords

ANTHRACYCLINE; GENE PRODUCT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CELL DEATH; CELL MATURATION; COLORECTAL CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; RNA INTERFERENCE; SPLEEN; T LYMPHOCYTE; TH2 CELL; TUMOR GROWTH;

MUS;

EID: 77956865312     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.14.12256     Document Type: Article

References (30)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:15-7.
2. Boutros M, Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev Genet 2008; 9:554-66.
3. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8:173-84.
4. Hede K. Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst 2005; 97:626-8.
5. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003; 8:762-8.
6. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002; 99:14849-54.
7. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003; 101:3157-63.
8. White PJ. Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol 2008; 35:1371-6.
9. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004; 5:355-65.
10. Recent patent applications in RNA interference. Nat Biotechnol 2007; 25:296.
11. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22:326-30.
12. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake and delivery with plasmid DNA. Biochemistry 2004; 43:13348-56.
13. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007; 104:4095-100.
14. Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009; 113:2646-54.
15. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34:263-4.
16. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5:834-9.
17. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR- and MDA5/RIG-I-mediated differential signaling. J Immunol 2008; 181:2694-704.
18. Sioud M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci 2008; 13:4379-92.
19. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996; 384:474-8.
20. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, et al. Conditional deletion of GATA3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol 2004; 5:1157-65.
21. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701.
22. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-50.
23. Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003; 278:157-69.
24. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, et al. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004; 21:719-31.
25. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8.
26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
27. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66.
28. + T helper cells. Cell 2006; 126:1121-33.
29. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007; 7:305-10.
30. Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 2001; 31:1780-9.